The second study follows a phase II trial that showed how the combination of taselisib plus fulvestrant had an acceptable side effect profile and clinical activity in patients with HER2 negative, HR positive advanced BC, with a numerically higher response in patients with PIK3CA mutations [77]. The gene discussed is PIK3CA; the disease is breast cancer.